[Federal Register Volume 75, Number 121 (Thursday, June 24, 2010)]
[Notices]
[Pages 36101-36102]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-15352]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0001]
Dermatologic and Ophthalmic Drugs Advisory Committee;
Cancellation
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The meeting of the Dermatologic and Ophthalmic Drugs Advisory
Committee scheduled for June 28, 2010, is cancelled. This meeting was
announced in the Federal Register of May 11, 2010 (75 FR 26264). The
meeting was to discuss new drug application (NDA) 22-340, voclosporin
10-milligram capsules, by Lux Biosciences Inc. This meeting has been
cancelled to allow time for the resolution of several outstanding
issues. The agency intends to continue evaluating NDA 22-340 and, as
needed, may schedule an advisory committee meeting in the future.
FOR FURTHER INFORMATION CONTACT: Yvette Waples, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, rm. 2417, Silver Spring, MD 20993-0002, 301-
796-9001, FAX: 301-847-8533, e-mail: [email protected], or FDA
Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in
the Washington, DC area), code 3014512534. Please call the Information
Line for up-to-date information on this meeting.
[[Page 36102]]
Dated: June 18, 2010.
Thinh Nguyen,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2010-15352 Filed 6-23-10; 8:45 am]
BILLING CODE 4160-01-S